Bio-Rad Laboratories, Inc. (BIO.B)

Bio-Rad Laboratories Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	395.8	488.1	403.8	434.22	470.78	662.21
Short-Term Investments	1,023	1,176	1,203	1,356	399.14	328.91
Cash & Short-Term Investments	1,419	1,665	1,607	1,791	869.92	991.12
Cash Growth	-12.57%	3.57%	-10.25%	105.84%	-12.23%	-11.08%
Accounts Receivable	464.7	452.5	489	494.65	423.54	419.42
Other Receivables	9.5	13.1	11.9	11.6	2.2	1.4
Receivables	474.2	465.6	500.9	506.25	425.74	420.82
Inventory	783.2	760	780.5	719.32	572.24	622.25
Prepaid Expenses	152	122.6	140	124.18	109.14	90.62
Restricted Cash	2	1.4	0.2	0.01	0.01	3.99
Other Current Assets	12	16.2	19.6	17.55	13.44	11.03
Total Current Assets	2,842	3,030	3,048	3,158	1,990	2,140
Property, Plant & Equipment	720.5	688.6	723.7	679.56	716.44	693.51
Long-Term Investments	5,057	4,838	7,697	8,830	14,386	9,560
Goodwill	578.7	410.5	413.6	406.49	347.34	291.92
Other Intangible Assets	388.4	293.6	320.5	332.15	253.94	199.5
Other Long-Term Assets	110.2	103.5	96.4	95.8	105.49	87.82
Total Assets	9,696	9,364	12,299	13,502	17,799	12,973
Accounts Payable	128.8	122.3	144.6	135.04	141.94	139.45
Accrued Expenses	182.8	124.2	139.9	194.79	312.97	256.93
Current Portion of Long-Term Debt	0.8	0.8	-	-	-	1.3
Current Portion of Leases	37.3	42.1	40.9	36.8	36.92	37.01
Current Income Taxes Payable	44.8	31.2	35.8	32.43	10.32	23.28
Current Unearned Revenue	50.2	-	-	-	50.85	42.47
Other Current Liabilities	77.6	147.2	161.6	169.65	127.94	131.1
Total Current Liabilities	522.3	467.8	522.8	568.71	680.94	631.54
Long-Term Debt	1,193	1,191	1,190	1,188	0	1.26
Long-Term Leases	164.6	140.6	175.1	163.73	186.45	186.13
Pension & Post-Retirement Benefits	-	56.9	59.5	45.3	73.8	94.8
Long-Term Deferred Tax Liabilities	872.6	818	1,476	1,770	3,065	2,077
Other Long-Term Liabilities	193.7	120.3	135.5	150.61	108.39	102.17
Total Liabilities	2,960	2,795	3,558	3,886	4,114	3,093
Common Stock	-	-	-	0	0	0
Additional Paid-In Capital	461.9	463.2	449.1	447.45	441.73	429.38
Retained Earnings	7,456	7,416	9,261	9,898	13,525	9,268
Treasury Stock	-1,015	-772.1	-632.5	-263.59	-106.29	-99.91
Comprehensive Income & Other	-166.8	-538.2	-336	-466.82	-175.55	282.46
Shareholders' Equity	6,737	6,569	8,741	9,615	13,685	9,880
Total Liabilities & Equity	9,696	9,364	12,299	13,502	17,799	12,973
Total Debt	1,395	1,375	1,406	1,388	223.38	225.69
Net Cash (Debt)	23.3	289.8	201.6	402.56	646.54	765.43
Net Cash Growth	-90.06%	43.75%	-49.92%	-37.74%	-15.53%	65.14%
Net Cash Per Share	0.85	10.27	6.90	13.52	21.40	25.38
Filing Date Shares Outstanding	26.97	28.01	28.52	29.6	29.93	29.84
Total Common Shares Outstanding	26.97	28.01	28.52	29.6	29.93	29.84
Working Capital	2,320	2,563	2,526	2,589	1,310	1,508
Book Value Per Share	249.75	234.52	306.51	324.89	457.20	331.05
Tangible Book Value	5,770	5,865	8,007	8,877	13,084	9,389
Tangible Book Value Per Share	213.90	209.39	280.77	299.93	437.12	314.59
Land	-	27.8	28.4	27.8	27.94	25.74
Buildings	-	426.3	419.8	393.6	385.8	363.05
Machinery	-	1,183	1,148	1,087	1,100	1,064

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q